Enhancement of recombinant human IL-24 (rhIL-24) protein production from site-specific integrated engineered CHO cells by sodium butyrate treatment
文献类型：期刊论文
| 作者 | Hua, Jilei1; Xu, Hanli1; Zhang, Yao1,2; Ge, Jianlin1; Liu, Mengzhe1; Wang, Yuqi1; Wei, Yuexian1; Shi, Yinan1,3; Hou, LingLing1; Jiang, Hong1 |
| 刊名 | BIOPROCESS AND BIOSYSTEMS ENGINEERING
 |
| 出版日期 | 2022-10-25 |
| 页码 | 13 |
| ISSN号 | 1615-7591 |
| 关键词 | rhIL-24 Serum-free culture Suspension culture CHO cells Sodium butyrate |
| DOI | 10.1007/s00449-022-02801-0 |
| 英文摘要 | Interleukin-24 (IL-24) has specific inhibitory effects on the proliferation of various tumor cells with almost no toxicity to normal cells. The antitumor activity of recombinant human IL-24 protein produced in mammalian cells is much higher than that of bacteria, but its expression level is extremely low. Sodium butyrate (NaBu) was utilized as a media additive to increase protein expression in Chinese hamster ovary cells. The site-specific integrated engineered cells FCHO/IL-24 were treated with NaBu under different culture conditions (10% and 0.5% serum adherent culture, 0.5% serum suspension culture). First, 3 days of 1 mmol/L NaBu treatment significantly increased rhIL-24 expression level in FCHO/IL-24 cells by 119.94 +/- 1.5% (**p < 0.01), 57.49 +/- 2.4% (**p < 0.01), and 20.17 +/- 3.03% (*p < 0.05) under the above culture conditions. Second, NaBu has a time- and dose-dependent inhibitory effect on FCHO/IL-24 proliferation and induces G0/G1 phase arrest. Under 10% and 0.5% serum adherent culture, G0/G1 phase cells were increased by 11.3 +/- 0.5% (**p < 0.01) and 15.0 +/- 2.6% (**p < 0.01), respectively. No induction of apoptosis was observed under a high dosage of NaBu treatment. These results suggest that NaBu increases rhIL-24 secretion via inhibiting cell cycle progression, thereby trapping cells in the highly productive G0/G1 phase. Finally, with increasing NaBu dose, glucose concentration increased (**p < 0.01) while lactic acid and ammonia concentrations reduced significantly (**p < 0.01) in 10% and 0.5% serum adherent culture supernatant. RNA-seq showed that NaBu treatment affected multiple tumor and immune-related pathways. In conclusion, NaBu treatment dramatically promoted rhIL-24 production in engineered FCHO/IL-24 cells by altering downstream pathways and inducing G0/G1 cell arrest with little effect on apoptosis. |
| WOS关键词 | GENE-EXPRESSION ; CULTURE ; MDA-7/IL-24 ; APOPTOSIS ; TRANSCRIPTOME ; INCREASES ; AUTOPHAGY ; GROWTH ; MDA-7 ; PA |
| 资助项目 | Fundamental Research Funds for the Central Universities[2021RC207] ; Beijing Natural Science Foundation[7214242] |
| WOS研究方向 | Biotechnology & Applied Microbiology ; Engineering |
| 语种 | 英语 |
| 出版者 | SPRINGER |
| WOS记录号 | WOS:000871861800001 |
| 资助机构 | Fundamental Research Funds for the Central Universities ; Beijing Natural Science Foundation |
| 源URL | [http://ir.ipe.ac.cn/handle/122111/55168]  |
| 专题 | 中国科学院过程工程研究所 |
| 通讯作者 | Hou, LingLing; Jiang, Hong |
| 作者单位 | 1.Beijing Jiaotong Univ, Coll Life Sci & Bioengn, 3 Shangyuancun, Beijing 100044, Peoples R China 2.Chinese Acad Sci, Inst Proc Engn, Natl Key Lab Biochem Engn, Beijing 100190, Peoples R China 3.China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing 100700, Peoples R China |
| 推荐引用方式 GB/T 7714 | Hua, Jilei,Xu, Hanli,Zhang, Yao,et al. Enhancement of recombinant human IL-24 (rhIL-24) protein production from site-specific integrated engineered CHO cells by sodium butyrate treatment[J]. BIOPROCESS AND BIOSYSTEMS ENGINEERING,2022:13. |
| APA | Hua, Jilei.,Xu, Hanli.,Zhang, Yao.,Ge, Jianlin.,Liu, Mengzhe.,...&Jiang, Hong.(2022).Enhancement of recombinant human IL-24 (rhIL-24) protein production from site-specific integrated engineered CHO cells by sodium butyrate treatment.BIOPROCESS AND BIOSYSTEMS ENGINEERING,13. |
| MLA | Hua, Jilei,et al."Enhancement of recombinant human IL-24 (rhIL-24) protein production from site-specific integrated engineered CHO cells by sodium butyrate treatment".BIOPROCESS AND BIOSYSTEMS ENGINEERING (2022):13. |
入库方式： OAI收割
来源：过程工程研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。